RESUMEN
Mefloquine has been one of the more valuable antimalarial drugs but has never reached its full clinical potential due to concerns about its neurologic side effects, its greater expense than that of other antimalarials, and the emergence of resistance. The commercial development of mefloquine superseded that of another quinolinyl methanol, WR030090, which was used as an experimental antimalarial drug by the U.S. Army in the 1970s. We evaluated a series of related 2-phenyl-substituted alkylaminoquinolinyl methanols (AAQMs) for their potential as mefloquine replacement drugs based on a series of appropriate in vitro and in vivo efficacy and toxicology screens and the theoretical cost of goods. Generally, the AAQMs were less neurotoxic and exhibited greater antimalarial potency, and they are potentially cheaper than mefloquine, but they showed poorer metabolic stability and pharmacokinetics and the potential for phototoxicity. These differences in physiochemical and biological properties are attributable to the "opening" of the piperidine ring of the 4-position side chain. Modification of the most promising compound, WR069878, by substitution of an appropriate N functionality at the 4 position, optimization of quinoline ring substituents at the 6 and 7 positions, and deconjugation of quinoline and phenyl ring systems is anticipated to yield a valuable new antimalarial drug.
Asunto(s)
Antimaláricos/farmacología , Mefloquina/análogos & derivados , Mefloquina/farmacología , Células 3T3 , Animales , Antimaláricos/síntesis química , Antimaláricos/química , Antimaláricos/economía , Antimaláricos/metabolismo , Antimaláricos/farmacocinética , Antimaláricos/toxicidad , Aotidae , Simulación por Computador , Evaluación Preclínica de Medicamentos , Eritrocitos/parasitología , Femenino , Concentración de Iones de Hidrógeno , Concentración 50 Inhibidora , Masculino , Mefloquina/síntesis química , Mefloquina/química , Mefloquina/economía , Mefloquina/metabolismo , Mefloquina/farmacocinética , Mefloquina/toxicidad , Ratones , Microscopía Confocal , Estructura Molecular , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Parasitemia/tratamiento farmacológico , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Solubilidad , Relación Estructura-ActividadRESUMEN
Over the past few years increasing attention has been focused on T-type calcium channels and their possible physiological and pathophysiological roles. Efforts toward elucidating the exact role(s) of these calcium channels have been hampered by the lack of T-type specific antagonists, resulting in the subsequent use of less selective calcium channel antagonists. In addition, the activity of these blockers often varies with cell or tissue type, as well as recording conditions. This review summarizes a variety of compounds that exhibit varying degrees of blocking activity towards T-type Ca2+ channels. It is designed as an aid for researchers in need of antagonists to study the biophysical and pathological nature of T-type channels, as well as a starting point for those attempting to develop potent and selective antagonists of the channel.
Asunto(s)
Antihipertensivos/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio Tipo T/fisiología , Anestésicos/química , Anestésicos/farmacología , Animales , Anticonvulsivantes/química , Anticonvulsivantes/farmacología , Antihipertensivos/química , Antipsicóticos/química , Antipsicóticos/farmacología , Bloqueadores de los Canales de Calcio/química , Humanos , Neuronas/efectos de los fármacos , Neuronas/fisiologíaRESUMEN
Accelerated Ca2+ entry may be one component of the pathway regulating the proliferative phenotype of some types of cancer. Thus, a pharmacological agent with the ability to retard Ca2+ influx in susceptible cancers might inhibit proliferation of them by a cytostatic mechanism rather than by inducing cytotoxicity. We have developed a chemical synthetic scheme that has produced a small library of novel compounds that block Ca2+ entry induced by occupancy of the P2 receptor in two prostate cancer cell lines and inhibit proliferation of these cells in vitro. One of the agents, named TH-1177, was used to treat severe combined immunodeficient mice inoculated with the human prostate cancer line PC-3. Although the doses used and treatment schedule were chosen arbitrarily, treatment extended the mean life span of mice bearing tumors by up to 38%. Treatment of mice without cancer at doses 18 times that used in mice with tumors was not associated with any obvious toxicity, either grossly or on histological examination. These results suggest that novel cytostatic agents with efficacy against human prostate cancer cells can be developed by chemical synthesis of agents directed at the Ca2+ entry pathway.